Myriad Genetics Inc at Goldman Sachs Healthcare Conference Transcript
Welcome, everybody. Good afternoon. My name is Matt Sykes. I'm the Life Science Tools and Diagnostics analyst at Goldman Sachs. And I have the pleasure of welcoming Paul Diaz, the President and CEO of Myriad Genetics. Paul, thank you very much for being here.
Yes. Great to be here.
Questions & Answers
Maybe if you could just kind of start out and talk about sort of the most recent quarter, but I think more importantly, sort of what you see over the course of this year, and kind of some of the things that have changed over the course of the last year and have during your tenure. I mean, I think there's been a pretty impressive reset of organic growth rate. And maybe talk about what you see as sort of the drivers of that continued growth over the course of this year.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |